title: [Treatment interruption in HIV infected patients: clinical and biological evolution].
abstract: OBJECTIVE
  The authors had for aim to evaluate the clinical and biological evolution in HIV-infected patients with viraemia lower than 30,000 copies/mL having decided to interrupt their treatment.
  
  
  METHODS
  Patients with highly active antiretroviral therapy (HAART) for more than 3 months followed by treatment interruption longer than 1 month were included in a retrospective analysis.
  
  
  RESULTS
  Forty-six patients having stopped treatment between November 1999 and July 2003 were included. The median duration of treatment interruption was 9.5 months. During the study, no clinical event occurred for 21 patients, and at least 1 clinical event occurred for the 25 others. The median CD4(+) cell counts (CD4) before and at the end of treatment interruption were 597/mm(3) and 437/mm(3), respectively (P<0.001). The median values of viral load before and at the end of treatment interruption were <50 and 23749 copies/mL, respectively (P<0.001). Among the 26 patients having started a new HAART, pre-treatment interruption and post-new HAART median CD4 (with a median delay after HAART of 9.7 months) were 548 and 432.5/mm(3) (P=0.02). Pre-treatment interruption and post-new HAART median viral load were 131.5 and 94.5 copies/mL (NS).
  
  
  CONCLUSIONS
  Treatment interruption must be used with caution in spite of the absence of virological impact, because CD4 cell count after new HAART is lower than CD4 preceding treatment interruption. Treatment interruption is contraindicated for patients with AIDS. Physicians must carefully follow other patients who decide on a treatment interruption.
authors.affiliation: Service de maladies infectieuses et tropicales, hôpital de la Croix-Rousse, 103, Grande rue de la Croix-Rousse, 69317 Lyon cedex 04, France.
authors.forename: M
authors.initials: M
authors.lastname: Giard
authors.forename: A
authors.initials: A
authors.lastname: Boibieux
authors.forename: B
authors.initials: B
authors.lastname: Ponceau
authors.forename: F
authors.initials: F
authors.lastname: Biron
authors.forename: E
authors.initials: E
authors.lastname: Braun
authors.forename: B
authors.initials: B
authors.lastname: Issartel
authors.forename: C
authors.initials: C
authors.lastname: Lalain
authors.forename: J
authors.initials: J
authors.lastname: Lippmann
authors.forename: F
authors.initials: F
authors.lastname: Daoud
authors.forename: C
authors.initials: C
authors.lastname: Delbrassine
authors.forename: C
authors.initials: C
authors.lastname: Delorme
authors.forename: C
authors.initials: C
authors.lastname: Chidiac
authors.forename: D
authors.initials: D
authors.lastname: Peyramond
mesh_terms: D000328:Adult; D000368:Aged; D023241:Antiretroviral Therapy, Highly Active; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D016312:Treatment Refusal